Janel Long-Boyle is a pharmacologist, a specialist in how medications and other substances affect the body. She helps provide drug therapy for pediatric patients, including those requiring bone marrow transplantation, those receiving chemotherapy to treat blood disorders or solid tumors, and those needing medication for primary immunodeficiency disorders. To ensure the best outcome for each child, she takes an individualized, patient-centered approach to drug therapy.
Long-Boyle's research focuses on improving drug therapies used in pediatric bone marrow transplantation and cancer treatments. This work includes developing mathematical models for dosing drugs more accurately, especially in infants and children, and for creating more personalized treatment regimens. She is the co-founder and clinical trials director of the Initiative for Pediatric Drug and Device Development, a partnership with the University of Maryland School of Pharmacy that promotes professional exploration of new and better treatments for children.
After earning her bachelor's degree in biochemistry at the University of Minnesota, Long-Boyle completed her doctor of pharmacy degree and a doctorate in experimental and clinical pharmacology at the University of Minnesota College of Pharmacy. She belongs to the American Society for Transplantation and Cellular Therapy, American Society for Clinical Pharmacology and Therapeutics, and International Society of Pharmacometrics.
